

James Foster

ASSOCIATE

Corporate
London

james.foster@wsgr.com
44-20-39634054



FOCUS AREAS

Corporate
Corporate Governance
Emerging Companies
Mergers & Acquisitions
Shareholder Engagement
and Activism

EXPERIENCE

James Foster is an associate in the London office of Wilson Sonsini Goodrich & Rosati, where he works with companies and investors in the technology, life sciences, and green energy sectors. From start-ups to the world's most valuable companies, James has advised clients on a wide range of corporate and commercial matters, including private M&A, fundraisings, joint ventures, technology commercialisation, and company law issues.

CREDENTIALS

Education

- Postgraduate Diploma in Law (GDL) and Legal Practice Course (LPC), BPP University, London, United Kingdom, 2012
- B.Sc. (Hons), Business Management, King's College London, 2010

Admissions

- Solicitor, England and Wales

MATTERS

Select Matters

James has advised:

- Chegg on its €385 million acquisition of Busuu
- Baylis Medical on the \$1.75 billion sale of its cardiology business to Boston Scientific
- Uber on the sale and restructuring of its interests in various joint ventures with Yandex
- Contentsquare on its acquisition of Hotjar
- Learnosity, a Battery Ventures portfolio company, on its acquisition of Questionmark, an assessments, proctoring, and reporting solutions provider
- Bain & Company on its acquisition of Tech Economy, a technology consultancy
- Snyc on its acquisition of FossID, a developer of automated Software Composition Analysis tools based in Sweden
- Snyc on its acquisition of DeepCodeAG, a provider of real-time semantic code analysis based in Switzerland
- Snap on various undisclosed transactions
- Cornerstone OnDemand, Inc., a global leader in people development solutions, on the UK aspects of its \$1.295 billion acquisition of Saba, a talent solution company
- Bavarian Nordic on its agreement to acquire the manufacturing and global rights to two commercial vaccines from GSK for €796 million
- Therachon, a clinical-stage biotechnology company focused on rare diseases, on its sale to Pfizer for up to \$810 million

- Battery Ventures on its acquisition of Guardsquare, a security company focused on protecting complex mobile applications
- RenalytixAI, a developer of AI-enabled clinical diagnostics for kidney disease, on its £22.25 million initial public offering
- General Electric on its acquisition of the thermal, renewable and grid businesses of Alstom for €12.35 billion (IFLR European M&A deal of the year 2016)
- DMGT as 52% shareholder of Zoopla on its IPO, with a market capitalisation of £919 million